French healthcare company Sanofi S.A. (Euronext Paris: SAN) (Nasdaq: SNY) and Provention Bio Inc announced on Monday an agreement for Sanofi to acquire US-based Provention Bio (Nasdaq:PRVB).
Sanofi will pay USD25.00 per share in cash, representing a total equity value of approximately USD2.9bn.
Provention Bio is a commercial-stage biopharmaceutical company with a focus on advancing the development and commercialisation of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated diseases.
Through this transaction Sanofi will acquire TZIELD (teplizumab-mzwv), which was approved in the United States last year as the first and only therapy to delay the onset of Stage 3 type 1 diabetes in adults and paediatric patients aged 8 years and older with Stage 2 type 1 diabetes.
Subject to the satisfaction or waiver of customary closing conditions, Sanofi expects to complete the acquisition in the second quarter of 2023.
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Aprecia names new chief commercial officer
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults
Arecor Therapeutics plc extends collaboration with Eli Lilly
OptiBiotix Health partners with Ravenswood for SlimBiome distribution in Australia and New Zealand
Boehringer Ingelheim granted European approval of oral liquid medication for feline diabetes